Nuclear receptors: emerging drug targets for parasitic diseases.
Nuclear receptors: emerging drug targets for parasitic diseases.
复制标题
核受体：寄生虫病的新兴药物靶点。
DOI：
10.1172/jci88890
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Mangelsdorf,DavidJ
中科院分区：
文献类型：
--
作者：
Wang,Zhu;Schaffer,NathanielE;Kliewer,StevenA;Mangelsdorf,DavidJ
寄生虫感染了全世界数十亿人。目前的治疗方法依赖于已经使用了几十年的一小部分药物。这些药物的一个缺点是它们不能针对寄生虫的难治性感染阶段。作为哺乳动物中众所周知的治疗靶点，核受体已经开始在寄生虫中进行研究，它们广泛分布并在控制代谢和发育转录网络中发挥关键作用。其中一种核受体是DAF-12，它是正常线虫发育所必需的，包括最重要的感染阶段。在这里，我们回顾了新出现的文献暗示DAF-12和其他潜在的核受体作为新的驱虫靶点。
Parasitic worms infect billions of people worldwide. Current treatments rely on a small group of drugs that have been used for decades. A shortcoming of these drugs is their inability to target the intractable infectious stage of the parasite. As well-known therapeutic targets in mammals, nuclear receptors have begun to be studied in parasitic worms, where they are widely distributed and play key roles in governing metabolic and developmental transcriptional networks. One such nuclear receptor is DAF-12, which is required for normal nematode development, including the all-important infectious stage. Here we review the emerging literature that implicates DAF-12 and potentially other nuclear receptors as novel anthelmintic targets.